HPV Status Improves Classification of Head and Neck Gray Zone Cancers.


Journal

Journal of dental research
ISSN: 1544-0591
Titre abrégé: J Dent Res
Pays: United States
ID NLM: 0354343

Informations de publication

Date de publication:
07 2019
Historique:
entrez: 9 7 2019
pubmed: 10 7 2019
medline: 16 7 2020
Statut: ppublish

Résumé

In epidemiologic studies, patients with head and neck squamous cell carcinoma (HNSCC) are classified mainly by the International Classification of Diseases (ICD) codes. However, some patients are of an unclear subsite, the "gray zone" cases, which could reflect ICD coding error, absence of primary subsite, or extensive primary tumors that cross over multiple subsites of the oral cavity and oropharynx. Patients with gray zone squamous cell carcinomas were compared with patients with oral cavity squamous cell carcinoma (OSCC) or oropharyngeal squamous cell carcinoma (OPSCC) and stratified by human papillomavirus (HPV) status that was determined by p16 immunostaining or HPV serology. Comparisons consisted of clinicodemographic features and prognostic outcomes presented by Kaplan-Meier curves and Cox proportional hazards regression models, reported as hazard ratios. There were 158 consecutive patients with gray zone HNSCC diagnosed at the Princess Margaret Cancer Center between 2006 and 2017: 66 had subsite coding discrepancies against the clinician's documentation ("discrepant" cases; e.g., the diagnosis by the clinician was OSCC, while the classification by ICD coding was OPSCC), while 92 were squamous cell carcinoma of unknown primary of the head and neck (SCCUPHN) after complete diagnostic workup. Comparators included 721 consecutive OSCC and 938 OPSCC adult cases. All HPV-positive cohorts (OPSCC, discrepant, and SCCUPHN) had similar clinicodemographic characteristics and better 3- and 5-y overall survival and disease-free survival than their HPV-negative counterparts. In contrast, HPV-negative discrepant cases had prognostic outcomes most similar to HPV-negative OPSCC cases, while HPV-negative SCCUPHN had survival outcomes most similar to those of patients with OSCC in this study. HPV-positive status can improve the classification of patients with unclear or discrepant oral/oropharyngeal subsite, an improvement over classification systems that are solely clinician defined or conducted through ICD coding. However, due to clinical practice, we could not make definitive reclassification for patients with HPV-negative gray zone HNSCC.

Identifiants

pubmed: 31282843
doi: 10.1177/0022034519853771
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

879-887

Commentaires et corrections

Type : ErratumIn

Auteurs

J Ren (J)

1 Department of Otolaryngology-Head and Neck Surgery, National Clinical Research Center for Geriatrics, West China Hospital, West China Medical School, Sichuan University, Chengdu, China.
2 Medical Biophysics, Princess Margaret Cancer Centre-University Health Network, University of Toronto, Toronto, Canada.

W Xu (W)

3 Department of Biostatistics, Princess Margaret Cancer Centre and Dalla Lana School of Public Health, Toronto, Canada.

J Su (J)

3 Department of Biostatistics, Princess Margaret Cancer Centre and Dalla Lana School of Public Health, Toronto, Canada.

X Ren (X)

4 Department of Economic Statistics, School of Statistics and Management, Shanghai University of Finance and Economics, Shanghai, China.

N Bender (N)

5 Infections and Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.

S Habbous (S)

2 Medical Biophysics, Princess Margaret Cancer Centre-University Health Network, University of Toronto, Toronto, Canada.

J R de Almeida (JR)

6 Department of Otolaryngology-Head and Neck Surgery, Princess Margaret Cancer Centre-University Health Network, University of Toronto, Toronto, Canada.

D P Goldstein (DP)

6 Department of Otolaryngology-Head and Neck Surgery, Princess Margaret Cancer Centre-University Health Network, University of Toronto, Toronto, Canada.

D Cheng (D)

2 Medical Biophysics, Princess Margaret Cancer Centre-University Health Network, University of Toronto, Toronto, Canada.

Z Chen (Z)

2 Medical Biophysics, Princess Margaret Cancer Centre-University Health Network, University of Toronto, Toronto, Canada.

M Mirshams (M)

2 Medical Biophysics, Princess Margaret Cancer Centre-University Health Network, University of Toronto, Toronto, Canada.

M Rahini (M)

2 Medical Biophysics, Princess Margaret Cancer Centre-University Health Network, University of Toronto, Toronto, Canada.

S H Huang (SH)

7 Department of Radiation Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada.

A Spreafico (A)

8 Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Center, University Health Network, University of Toronto, Toronto, Canada.

A Hansen (A)

8 Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Center, University Health Network, University of Toronto, Toronto, Canada.

J Kim (J)

7 Department of Radiation Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada.

J Waldron (J)

7 Department of Radiation Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada.

B Perez-Ordonez (B)

9 Department of Laboratory Medicine and Pathology, University Health Network, University of Toronto, Toronto, Canada.

Y Zhao (Y)

1 Department of Otolaryngology-Head and Neck Surgery, National Clinical Research Center for Geriatrics, West China Hospital, West China Medical School, Sichuan University, Chengdu, China.

R Hung (R)

10 Prosserman Centre for Population Health Research, Lunenfeld Tanenbaum Research Institute, Sinai Health System, Toronto, Canada.
11 Dalla Lana School of Public Health, University of Toronto, Toronto, Canada.

T Waterboer (T)

5 Infections and Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.

G Liu (G)

2 Medical Biophysics, Princess Margaret Cancer Centre-University Health Network, University of Toronto, Toronto, Canada.
8 Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Center, University Health Network, University of Toronto, Toronto, Canada.
11 Dalla Lana School of Public Health, University of Toronto, Toronto, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH